These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543 [TBL] [Abstract][Full Text] [Related]
30. [Growth control of breast cancer in relation to hormones]. Tominaga T; Yoshida Y Gan To Kagaku Ryoho; 1989 Dec; 16(12):3685-90. PubMed ID: 2688558 [TBL] [Abstract][Full Text] [Related]
31. Resistance to endocrine therapy in breast cancer. Kurebayashi J Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353 [TBL] [Abstract][Full Text] [Related]
32. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012 [TBL] [Abstract][Full Text] [Related]
33. Staying the distance: avoiding the proteasomal trap. Downes M; Evans RM Cancer Cell; 2008 Mar; 13(3):184-5. PubMed ID: 18328421 [TBL] [Abstract][Full Text] [Related]
34. Membrane-initiated signaling of estrogen in the brain. Rønnekleiv OK; Malyala A; Kelly MJ Semin Reprod Med; 2007 May; 25(3):165-77. PubMed ID: 17447206 [TBL] [Abstract][Full Text] [Related]
35. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Márquez DC; Chen HW; Curran EM; Welshons WV; Pietras RJ Mol Cell Endocrinol; 2006 Feb; 246(1-2):91-100. PubMed ID: 16388889 [TBL] [Abstract][Full Text] [Related]
36. Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer. McCafferty MP; McNeill RE; Miller N; Kerin MJ Breast Cancer Res Treat; 2009 Aug; 116(3):425-32. PubMed ID: 19507020 [TBL] [Abstract][Full Text] [Related]
37. Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? Sheikh MS; Garcia M; Pujol P; Fontana JA; Rochefort H Invasion Metastasis; 1994-1995; 14(1-6):329-36. PubMed ID: 7657526 [TBL] [Abstract][Full Text] [Related]
38. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401 [TBL] [Abstract][Full Text] [Related]
39. Sex hormone receptors in breast cancer. D'Abreo N; Hindenburg AA Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004 [TBL] [Abstract][Full Text] [Related]
40. Enhancing the efficacy of hormonal agents with selected targeted agents. Johnston SR Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]